title: A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
authors.affiliation: AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. dearg.brown@astrazeneca.com
authors.forename: Dearg S
authors.initials: DS
authors.lastname: Brown
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Belfield
authors.forename: George R
authors.initials: GR
authors.lastname: Brown
authors.forename: Douglas
authors.initials: D
authors.lastname: Campbell
authors.forename: Alan
authors.initials: A
authors.lastname: Foubister
authors.forename: David J
authors.initials: DJ
authors.lastname: Masters
authors.forename: Kurt G
authors.initials: KG
authors.lastname: Pike
authors.forename: Wendy L
authors.initials: WL
authors.lastname: Snelson
authors.forename: Stuart L
authors.initials: SL
authors.lastname: Wells
mesh_terms: D000577:Amides / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D018501:Antirheumatic Agents / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D066298:In Vitro Techniques; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D051381:Rats; D013329:Structure-Activity Relationship; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000577:Amides; D018501:Antirheumatic Agents; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D048051:p38 Mitogen-Activated Protein Kinases